Sodium alginate
As of the edition of 20 October 2026, Sodium alginate is a drug: marketed, first approved in 1994 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1994
- Kind
- Unknown
- Brand name
- Gaviscon Nourrissons
- First approved
- 5 September 1994 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Reckitt Benckiser
- Registered trials
- 5, 0 stopped early
- Disease areas
- Digestive system; Lungs and airways; Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 3 | 2 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| TTY Biopharm | Lead sponsor of trials | 2011 to now |
| Tecnoquimicas | Lead sponsor of trials | 2023 to now |